Clinical Trial Update: Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on MBP-426 for second-line gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and esophageal adenocarcinoma (Phase 1/Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• MBP-426

Snippet

Sponsor: Mebiopharm Co., Ltd | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: UNKNOWN